These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 15858476

  • 1. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L.
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [Abstract] [Full Text] [Related]

  • 2. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 3. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W.
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R.
    Cancer; 2000 Oct 15; 89(8):1835-44. PubMed ID: 11042581
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K.
    Clin Exp Dermatol; 2005 Jan 15; 30(1):46-8. PubMed ID: 15663503
    [Abstract] [Full Text] [Related]

  • 11. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM.
    J Cutan Pathol; 2005 Oct 15; 32(9):616-21. PubMed ID: 16176299
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
    Viguier M, Bachelez H, Brice P, Rivet J, Dubertret L.
    Ann Dermatol Venereol; 2002 Oct 15; 129(10 Pt 1):1152-5. PubMed ID: 12442128
    [Abstract] [Full Text] [Related]

  • 14. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 15; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK, Wittekind C, Niederwieser D.
    Dtsch Med Wochenschr; 2007 Aug 15; 132(33):1688-91. PubMed ID: 17713864
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.